Primer: Luye Pharma Group (2186 HK) - Aug 2026
Luye Pharma is at a pivotal point, with a portfolio of newly launched innovative drugs in high-growth therapeutic areas like Oncology and...
89 Views
Technically Speaking Breakouts & Breakdowns - HONG KONG (August 2026)
Genscript shares gain after the company announced it will provide wet-lab services to companies participating in Eli Lilly's TundeLab, helping them...
118 Views
3SBio Inc (1530 HK): Licensing Deal a Market Hit; Will It Continue?
3SBio signed $6B outlicensing deal with Pfizer for SSGJ-707, resulting in spectacular rally in 3SBio shares. Global trial initiation of SSGJ-707...
394 Views
China Traditional Chinese Medicine (570 HK): Disaster as Offer Lapses, Potential Deal Break Price
This deal break caught many, including me, off guard. There are lessons to be learnt and questions to be asked. Shareholders will have a bruising...
1.5k Views
APAC Healthcare Weekly (August 23) – Henlius Bio, Wuxi XDC, Chugai Pharma, Daiichi Sankyo, Celltrion
Henlius strikes biosimilar commercialization deal with Sandoz. Chugai signs exclusive license deal with GSK for anti-dengue virus antibody....
100 Views